ifenprodil has been researched along with Akinetic-Rigid Variant of Huntington Disease in 4 studies
ifenprodil: NMDA receptor antagonist
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trippier, PC | 1 |
| Jansen Labby, K | 1 |
| Hawker, DD | 1 |
| Mataka, JJ | 1 |
| Silverman, RB | 1 |
| Tallaksen-Greene, SJ | 1 |
| Janiszewska, A | 1 |
| Benton, K | 1 |
| Ruprecht, L | 1 |
| Albin, RL | 1 |
| Milnerwood, AJ | 1 |
| Kaufman, AM | 1 |
| Sepers, MD | 1 |
| Gladding, CM | 1 |
| Zhang, L | 1 |
| Wang, L | 1 |
| Fan, J | 1 |
| Coquinco, A | 1 |
| Qiao, JY | 1 |
| Lee, H | 1 |
| Wang, YT | 1 |
| Cynader, M | 1 |
| Raymond, LA | 1 |
| Gogas, KR | 1 |
2 reviews available for ifenprodil and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; | 2013 |
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
Topics: Animals; Brain Ischemia; Clinical Trials as Topic; Disease Models, Animal; Excitatory Amino Acid Ant | 2006 |
2 other studies available for ifenprodil and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Female; Huntington Disease; Kaplan-Meier Estimate; | 2010 |
Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Topics: Animals; Apoptosis; Cerebral Cortex; Coculture Techniques; Corpus Striatum; Disease Models, Animal; | 2012 |